An analysis of controlled human infection studies registered on ClinicalTrials.gov

Objectives Controlled human infection studies (CHIS) involve intentional exposure of human volunteers to infectious agents. A previous systematic review found that adverse event (AE) reporting across CHIS is inconsistent, which makes data aggregation and reuse difficult. We hypothesised that data ma...

Full description

Saved in:
Bibliographic Details
Main Authors: James Wilkinson, Joshua Osowicki, Euzebiusz Jamrozik, Ian J Saldanha, Meta Roestenberg, Danny Toomey, Jupiter Adams-Phipps, John Pietro, Jake Littman, Steffen Kamenicek, Daniel Kaufman
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/2/e085250.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823865268311425024
author James Wilkinson
Joshua Osowicki
Euzebiusz Jamrozik
Ian J Saldanha
Meta Roestenberg
Danny Toomey
Jupiter Adams-Phipps
John Pietro
Jake Littman
Steffen Kamenicek
Daniel Kaufman
author_facet James Wilkinson
Joshua Osowicki
Euzebiusz Jamrozik
Ian J Saldanha
Meta Roestenberg
Danny Toomey
Jupiter Adams-Phipps
John Pietro
Jake Littman
Steffen Kamenicek
Daniel Kaufman
author_sort James Wilkinson
collection DOAJ
description Objectives Controlled human infection studies (CHIS) involve intentional exposure of human volunteers to infectious agents. A previous systematic review found that adverse event (AE) reporting across CHIS is inconsistent, which makes data aggregation and reuse difficult. We hypothesised that data may be more easily aggregated using a clinical trial registry such as ClinicalTrals.gov, the largest publicly accessible registry of clinical trial data. The objectives of the current analysis were to (1) evaluate the use of ClinicalTrials.gov for CHIS data reporting and (2) compare CHIS clinical trial participant flow and AE reporting in ClinicalTrials.gov with the same data in corresponding published articles.Design ClinicalTrials.gov records that described a CHIS were included and data were accessed using the Aggregated Analysis of ClinicalTrials.gov application programming interface. These data were compared with results extracted from publications associated with included records’ NCT identifiers and compared in groups stratified by sponsor type, cohort size and risk of bias. Results were considered discrepant if the same number was reported unambiguously differently in the clinical trial record and its associated publications. The frequencies of these discrepancies were used to quantify the differences between reporting in ClinicalTrials.gov records and publications of the same results.Results We screened 5131 ClinicalTrials.gov records for inclusion, reviewed 410 records in full and included 344 records. The overall prevalence of any discrepancy was 40%. Compared with their respective groups, significant discrepancies were observed in publicly funded trials, trials in the third quartile of study size and trials with a high risk of bias in selection of the reported result. Five studies reported a total of five serious AEs in ClinicalTrials.gov records but not in any associated publications.Conclusion We identified an overall prevalence of discrepancy of 40% in CHIS, which is comparable with the prevalence observed in other types of clinical trials. In general, medium-sized, publicly funded trials tended to have more discrepancies in reporting, which may reflect the resources typically available to large, privately funded trials or the relative ease of reporting in smaller trials with fewer overall AEs. These results highlight the need to facilitate clear and consistent reporting in CHIS.PROSPERO registration number CRD42022330047.
format Article
id doaj-art-921984838e7344aea26a8dea798575f1
institution Kabale University
issn 2044-6055
language English
publishDate 2025-02-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-921984838e7344aea26a8dea798575f12025-02-08T08:35:10ZengBMJ Publishing GroupBMJ Open2044-60552025-02-0115210.1136/bmjopen-2024-085250An analysis of controlled human infection studies registered on ClinicalTrials.govJames Wilkinson0Joshua Osowicki1Euzebiusz Jamrozik2Ian J Saldanha3Meta Roestenberg4Danny Toomey5Jupiter Adams-Phipps6John Pietro7Jake Littman8Steffen Kamenicek9Daniel Kaufman101 1Day Sooner Research Team, Claymont, Delaware, USA4 Tropical Diseases Research Group, Murdoch Children`s Research Institute, Parkville, Victoria, Australia7 Ethox and Pandemic Sciences Institute, University of Oxford, Oxford, UK6 Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA5 Leiden University Medical Center, Center for Infectious Diseases, Leiden, Zuid-Holland, Netherlands1 1Day Sooner Research Team, Claymont, Delaware, USA1 1Day Sooner Research Team, Claymont, Delaware, USA1 1Day Sooner Research Team, Claymont, Delaware, USA1 1Day Sooner Research Team, Claymont, Delaware, USA1 1Day Sooner Research Team, Claymont, Delaware, USA1 1Day Sooner Research Team, Claymont, Delaware, USAObjectives Controlled human infection studies (CHIS) involve intentional exposure of human volunteers to infectious agents. A previous systematic review found that adverse event (AE) reporting across CHIS is inconsistent, which makes data aggregation and reuse difficult. We hypothesised that data may be more easily aggregated using a clinical trial registry such as ClinicalTrals.gov, the largest publicly accessible registry of clinical trial data. The objectives of the current analysis were to (1) evaluate the use of ClinicalTrials.gov for CHIS data reporting and (2) compare CHIS clinical trial participant flow and AE reporting in ClinicalTrials.gov with the same data in corresponding published articles.Design ClinicalTrials.gov records that described a CHIS were included and data were accessed using the Aggregated Analysis of ClinicalTrials.gov application programming interface. These data were compared with results extracted from publications associated with included records’ NCT identifiers and compared in groups stratified by sponsor type, cohort size and risk of bias. Results were considered discrepant if the same number was reported unambiguously differently in the clinical trial record and its associated publications. The frequencies of these discrepancies were used to quantify the differences between reporting in ClinicalTrials.gov records and publications of the same results.Results We screened 5131 ClinicalTrials.gov records for inclusion, reviewed 410 records in full and included 344 records. The overall prevalence of any discrepancy was 40%. Compared with their respective groups, significant discrepancies were observed in publicly funded trials, trials in the third quartile of study size and trials with a high risk of bias in selection of the reported result. Five studies reported a total of five serious AEs in ClinicalTrials.gov records but not in any associated publications.Conclusion We identified an overall prevalence of discrepancy of 40% in CHIS, which is comparable with the prevalence observed in other types of clinical trials. In general, medium-sized, publicly funded trials tended to have more discrepancies in reporting, which may reflect the resources typically available to large, privately funded trials or the relative ease of reporting in smaller trials with fewer overall AEs. These results highlight the need to facilitate clear and consistent reporting in CHIS.PROSPERO registration number CRD42022330047.https://bmjopen.bmj.com/content/15/2/e085250.full
spellingShingle James Wilkinson
Joshua Osowicki
Euzebiusz Jamrozik
Ian J Saldanha
Meta Roestenberg
Danny Toomey
Jupiter Adams-Phipps
John Pietro
Jake Littman
Steffen Kamenicek
Daniel Kaufman
An analysis of controlled human infection studies registered on ClinicalTrials.gov
BMJ Open
title An analysis of controlled human infection studies registered on ClinicalTrials.gov
title_full An analysis of controlled human infection studies registered on ClinicalTrials.gov
title_fullStr An analysis of controlled human infection studies registered on ClinicalTrials.gov
title_full_unstemmed An analysis of controlled human infection studies registered on ClinicalTrials.gov
title_short An analysis of controlled human infection studies registered on ClinicalTrials.gov
title_sort analysis of controlled human infection studies registered on clinicaltrials gov
url https://bmjopen.bmj.com/content/15/2/e085250.full
work_keys_str_mv AT jameswilkinson ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT joshuaosowicki ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT euzebiuszjamrozik ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT ianjsaldanha ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT metaroestenberg ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT dannytoomey ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT jupiteradamsphipps ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT johnpietro ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT jakelittman ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT steffenkamenicek ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT danielkaufman ananalysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT jameswilkinson analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT joshuaosowicki analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT euzebiuszjamrozik analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT ianjsaldanha analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT metaroestenberg analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT dannytoomey analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT jupiteradamsphipps analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT johnpietro analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT jakelittman analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT steffenkamenicek analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov
AT danielkaufman analysisofcontrolledhumaninfectionstudiesregisteredonclinicaltrialsgov